Home
Publication

Publications

Experience the intersection of innovation and reliability in our suite of published works: Explore breakthrough case studies, gain insights from commentaries, and discover the prestige of scientific articles and posters.

Posters

These scientific posters, presented both by our expert team and by clients utilizing our models at conferences around the globe, stand as testaments to the impactful research facilitated by our genetically modified models.

See more
(Seattle Children's) A Bispecific PD-L1:CD3 T-cell Engager Potently Kills Intractable Primary And Metastatic Intracranial Tumors

PD-L1:CD3 TCE for intracranial tumors

May 2026
(Seattle Children's) Expanded Therapeutic Window of Potent Bispecific PD-L1 T Cell Engager with Novel Best-in-Class CD3 Binder

Testing efficacy and safety of new TCEs

May 2026
(Crown Bio) Enhancing the Predictability of Human Pharmacokinetics for Antibody-Drug Conjugates Using Human FcRn Transgenic Mice

Predicting human PK of ADCs with genO-hSA/hFcRn mice

Apr 2026

Webinars

These webinars bring together expert voices to explore emerging breakthroughs, evolving methodologies, and key conversations shaping preclinical research. They provide a dynamic forum where participants and those who revisit the sessions gain a clear understanding of the scientific advances driving progress in the preclinical field.

See more
Advancing T‑cell engagers addressing key efficacy and safety challenges

T-cell engager efficacy/safety

June 4, 2026
Unlocking Treg therapeutics: cutting-edge preclinical models for CCR8-targeting agents in efficacy and safety assessment

CCR8/CCL1 & Treg

January 27, 2026
Exploring tumor-immune interactions in genO‑BRGSF‑HIS mice: myeloid and lymphoid cell recruitment dynamics

HIS mice & efficacy

November 20, 2025
Safety assessment of biologics in genO-BRGSF HIS: a highly predictive and translational mouse model

HIS mice & safety

July 7, 2025
T-cell engager development: the role of hCD3 models in safety and efficacy assessment

CD3 mice for safety & efficacy

September 25, 2025

Scientific articles

genOway proudly stands at the forefront of scientific advancements, with a prestigious list of clients whose research using our models has been published in peer-reviewed scientific journals. These publications bear testimony to the reliability, versatility, and impact of our solutions.

See more

Commentaries

These commentaries serve as beacons of knowledge, offering a nuanced perspective on the cutting-edge developments that define genOway's scientific environment. A collection of insightful thoughts that provide a deep dive into the latest trends, challenges, and advancements in the fields of genetic engineering, biomedical research, and beyond.

See more
Enabling the development of next-generation PD-1/PD-L1 combination immunotherapies with advanced humanized models

mouse models for next-generation PD-1 therapies

12 min read
-
Aug 2026
Preclinical assessment of therapeutics beyond the blood-brain barrier: towards more predictive preclinical models

Drug shuttling across the BBB

8 min read
-
Jul 2026
Guide: Mice with a human immune system (HIS mice) for the assessment of therapeutics: practical considerations for translational research

HIS mice for therapeutic antibody assessment

15 min read
-
Jul 2026
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe